Comparison of 6 months Isoniazid v/s 3 months Isoniazid - Rifampicin Therapy for Prevention of Tuberculosis in Children Suffering from Latent Tuberculosis Infectio
Phase 3
Completed
- Conditions
- Health Condition 1: A150- Tuberculosis of lungHealth Condition 2: A150- Tuberculosis of lung
- Registration Number
- CTRI/2022/02/040539
- Lead Sponsor
- DR SHIVANGI SINHA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 64
Inclusion Criteria
children (6-14years)with LTBI living with sputum smear positive adult TB patients undergoing DOTS
Exclusion Criteria
children in contact with adults having multidrug resistant TB (MDR-TB) or Extensively drug resistanT TB(XDR-TB).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of children with LTBI developing Tuberculosis at 9 months after receiving treatment with 3 months HR v/s 6 months INH will be calculated and compared. <br/ ><br>Timepoint: 2 years
- Secondary Outcome Measures
Name Time Method both groups will be compared in terms of adverse effectsTimepoint: 2 years